en · de · es · fr · pt
melanotan-2-notes.peptides6579.com › Info › Identity And Chemical Background — Field Notes

Identity And Chemical Background — Field Notes

By Editorial Desk · published 2026-02-07 · last reviewed 2026-03-01 · Info

A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms differ
Molecular weightApproximately 1024 g/molCalculated for the free base
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and polar solventsPoorly soluble in non-polar solvents
Typical storage-20 degrees Celsius, dry, protected from lightRefers to the solid form

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Related pages on this site

Background and Mechanism of Melanotan-2

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Notes from published material

=== Fish === Aquatic animals that swim by using an elongated fin along the dorsum, ventrum, or in pairs on their lateral margins (such as oarfish, knifefish, cephalopods) have all come to the same ratio of amplitude to wavelength of fin undulation to maximize speed, 20:1. Mudskippers and exhibit a number of adaptations to semi-terrestrial lifestyle which are also usually attributed to Devonian tetrapodomorphs such as Tiktaalik: breathing surface air, having eyes positioned on top of the head, propping up and moving on land using strong fins. Pacific leaping blennies also resemble mudskippers though they are not related.

=== Pharmacokinetics === The pharmacokinetics of phenylpiracetam in humans are unpublished. In any case, the drug is described as having an oral bioavailability of approximately 100%, as having an onset of action of less than 1 hour, as not being metabolized, as being excreted unchanged about 40% in urine and 60% in bile and sweat, and as having an elimination half-life of 3 to 5 hours. In rodents, its absorption occurs within 1 hour with oral administration or intramuscular injection and its elimination half-life is 2.5 to 3 hours.

Connective tissue disorders: Scleroderma Systemic lupus erythematosus Rheumatoid arthritis Sjögren's disease Dermatomyositis Polymyositis Mixed connective tissue disease Cold agglutinin disease Ehlers–Danlos syndrome Eating disorders: Anorexia nervosa Obstructive disorders: Atherosclerosis Buerger's disease Takayasu's arteritis Subclavian aneurysms Thoracic outlet syndrome Drugs: Beta-blockers Cytotoxic drugs – particularly chemotherapeutics and most especially bleomycin Cyclosporin Bromocriptine Ergotamine Sulfasalazine Anthrax vaccines whose primary ingredient is the Anthrax Protective Antigen Stimulant medications, such as those used to treat ADHD (amphetamine and methylphenidate) OTC pseudoephedrine medications (Chlor-Trimeton, Sudafed, others) Occupation: Jobs involving vibration, particularly drilling and prolonged use of a string trimmer (weed whacker), experience vibration white finger Exposure to vinyl chloride, mercury Exposure to the cold (e.g., by working as a frozen food packer) Others: Physical trauma to the extremities Lyme disease Hypothyroidism Cryoglobulinemia Cancer Myalgic encephalomyelitis/chronic fatigue syndrome Reflex sympathetic dystrophy Carpal tunnel syndrome Magnesium deficiency Empty nose syndrome Multiple sclerosis Erythromelalgia (clinically presenting as the opposite of Raynaud's, with hot and warm extremities, often co-exists in patients with Raynaud's) Chilblains (also clinically presenting as the opposite of Raynaud's, with hot and itchy extremities; however, it affects smaller areas than erythromelalgia, for instance, the tip of a toe rather than the whole foot) Raynaud syndrome can precede these other diseases by many years, making it the first presenting symptom. This may be the case in the CREST syndrome, of which Raynaud's is a part. Patients with secondary Raynaud's can also have symptoms related to their underlying diseases. Raynaud's phenomenon is the initial symptom that presents for 70% of patients with scleroderma, a skin and joint disease. When Raynaud's phenomenon is limited to one hand or one foot, it is referred to as unilateral Raynaud's. This is an uncommon form, and it is always secondary to local or regional vascular disease. It commonly progresses within several years to affect other limbs as the vascular disease progresses.

The use of cationic micelles of cetrimonium chloride, benzethonium chloride, and cetylpyridinium chloride can accelerate chemical reactions between negatively charged compounds (such as DNA or Coenzyme A) in an aqueous environment up to 5 million times. Unlike conventional micellar catalysis, the reactions occur solely on the charged micelles' surface. Micelle formation is essential for the absorption of fat-soluble vitamins and complicated lipids within the human body. Bile salts formed in the liver and secreted by the gall bladder allow micelles of fatty acids to form. This allows the absorption of complicated lipids (e.g., lecithin) and lipid-soluble vitamins (A, D, E, and K) within the micelle by the small intestine. During the process of milk-clotting, proteases act on the soluble portion of caseins, κ-casein, thus originating an unstable micellar state that results in clot formation. Micelles can also be used for targeted drug delivery as gold nanoparticles.

Sources: en.wikipedia.org

Further detail

A tandem mass spectrometer is one capable of multiple rounds of mass spectrometry, usually separated by some form of molecule fragmentation. For example, one mass analyzer can isolate one peptide from many entering a mass spectrometer. A collision cell then stabilizes the peptide ions while they collide with a gas, causing them to fragment by collision-induced dissociation (CID). A further mass analyzer then sorts the fragments produced from the peptides. Tandem MS can also be done in a single mass analyzer over time, as in a quadrupole ion trap. There are various methods for fragmenting molecules for tandem MS, including collision-induced dissociation (CID), electron capture dissociation (ECD), electron transfer dissociation (ETD), infrared multiphoton dissociation (IRMPD), blackbody infrared radiative dissociation (BIRD), electron-detachment dissociation (EDD) and surface-induced dissociation (SID). An important application using tandem mass spectrometry is in protein identification. Tandem mass spectrometry enables a variety of experimental sequences. Many commercial mass spectrometers are designed to expedite the execution of such routine sequences as selected reaction monitoring, precursor ion scanning, product ion scanning, and neutral loss scanning.

== Marketing controversies == Exaggerated claims about the health benefits of goji berry and derived products have triggered strong reactions from government regulatory agencies. In 2019–2020, the U.S. Food and Drug Administration (FDA) placed two goji product distributors on notice with warning letters about unproven therapeutic benefits. The advertisers' statements were in violation of the United States Food, Drug and Cosmetic Act [21 USC/321 (g)(1)] because they "establish[ed] the product as a drug intended for use in the cure, mitigation, treatment, or prevention of disease" when goji ingredients have had no such scientific evaluation. Additionally stated by the FDA, the goji products are "not generally recognized as safe and effective for the referenced conditions" and therefore must be treated as a "new drug" under Section 21(p) of the Act. New drugs may not be legally marketed in the United States without prior approval of the FDA. In January 2007, marketing statements for a goji juice product were the subject of an investigative report by consumer advocacy program Marketplace produced by Canadian public broadcaster CBC. In the interview, Earl Mindell (then working for direct-marketing company FreeLife International, Inc.) falsely claimed the Memorial Sloan-Kettering Cancer Center in New York had completed clinical studies showing that use of wolfberry juice would prevent 75% of human breast cancer cases.

According to the manufacturer's website, the insulin's action profile in cats was similar to that of NPH insulin, and it lowered blood sugar quickly, but for only about 6–8 hours. Vetsulin was recalled in the US in November 2009 due to inconsistent strength; it was available again as of April 2013. Two ultra-slow time-release synthetic human insulins became available in 2004 and 2005, generically known as insulin detemir (Levemir) and insulin glargine (Lantus). Studies have had good results with insulin glargine in cats. Follow-up research shows that Levemir can be used with a similar protocol and that either insulin on this protocol can lead uncomplicated feline cases to remission, with the most success being in cats who start on these protocols as soon as possible after diagnosis.

=== "Guttergate" === On Friday 24 August 2007, the Seven Network broadcast details obtained from players' confidential medical records on its nightly news program. It allegedly purchased these details for $3,000 from a woman who found them in a gutter outside a medical clinic in Melbourne – leading to the nickname "Guttergate" for the incident. The network said that these records contained details of illicit, non-performance-enhancing drug-taking by players at a particular club in the AFL. The name of the club involved was revealed by Seven on air, but not the names of the players. Seven had promised to reveal the names of the players before the end of the program, but since anonymity was guaranteed by the AFL's three-strikes policy, the AFL obtained a court injunction from the Supreme Court of Victoria to suppress the release of the names – this injunction continues to prevent the publication of any part of the records, including any subsequent publication of the name of the club. At first, Seven vigorously defended its broadcast and stated that it had done so only for the purpose of highlighting the issue of drugs in sport. It challenged the injunction, then faced a backlash both from the AFL and the AFL players themselves. As a result, the players boycotted Seven, refusing to answer any questions posed by its journalists. Seven was not invited to (and, had it still arrived, would have been actively denied entry to) an AFL Players Association (AFLPA) press conference.

For more than ten years, the U.S. has been funding Plan Colombia, which aims to combat illegal drugs production in the country, especially the growing of coca, the plant from which cocaine is produced. Former President Obama's top drug policy adviser, R. Gil Kerlikowske, announced a drug plan in May 2010 emphasizing prevention and treatment in the United States.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

How is melanotan-2 distinguished from afamelanotide?

Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.

Why does the compound appear in tanning-related discussion?

Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

Network